Lesley Ann Calhoun - Jun 5, 2024 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
Director
Signature
/s/ Douglas Barry, as attorney-in-fact
Stock symbol
TNGX
Transactions as of
Jun 5, 2024
Transactions value $
$36,039
Form type
4
Date filed
6/7/2024, 05:16 PM
Previous filing
Mar 4, 2024
Next filing
Sep 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNGX Common Stock Award $0 +6.25K +125% $0.00 11.3K Jun 5, 2024 Direct F1
transaction TNGX Common Stock Sale $36K +5K +400% $7.21 6.25K Jun 5, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNGX Stock Option (Right to Buy) Award $0 +37.5K $0.00 37.5K Jun 5, 2024 Common Stock 37.5K $7.41 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2025 and (iii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2 The reported sale occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2023.
F3 Represents the weighted average sales price per share. The shares sold at prices ranging from $7.01 to $7.38 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4 This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 5, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.